- $16.02bn
- $11.57bn
- $3.24bn
- 72
- 26
- 98
- 73
RCS - Moderna Inc - Moderna’s COVID-19 Vaccine SARS-COV-2 Variant JN.1
AnnouncementREG - Stock Exch Notice - Admission to Trading - 02/09/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Stock Exch Notice - Admission to Trading - 30/08/2024
AnnouncementREG - Stock Exch Notice - Admission to Trading - 27/08/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementRCS - Moderna Inc - Moderna Receives Approval for RSV Vaccine mRESVIA
AnnouncementREG - Stock Exch Notice - Admission to ISM - 13/08/2024
AnnouncementREG - Stock Exch Notice - Admission to Trading - 12/08/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Stock Exch Notice - Admission to Trading - 06/08/2024
AnnouncementREG - Stock Exch Notice - Admission to Trading - 26/07/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - Stock Exch Notice - Admission to Trading - 12/07/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementRCS - Moderna Inc - EMA Committee For Medicinal Products For Human Use
AnnouncementREG - Official List - Amendment Notice
Announcement